# A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

> **NCT03523858** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 927 (actual)

## Conditions studied

- Progressive Multiple Sclerosis (PMS)

## Interventions

- **DRUG:** Ocrelizumab

## Key facts

- **NCT ID:** NCT03523858
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-05-28
- **Primary completion:** 2026-10-22
- **Final completion:** 2026-10-22
- **Target enrollment:** 927 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03523858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03523858, "A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03523858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*